vs
STANDARD BIOTOOLS INC.（LAB）与OptimizeRx Corp（OPRX）财务数据对比。点击上方公司名可切换其他公司
OptimizeRx Corp的季度营收约是STANDARD BIOTOOLS INC.的1.6倍（$32.2M vs $19.6M），OptimizeRx Corp净利率更高（15.6% vs -177.4%，领先193.0%），OptimizeRx Corp同比增速更快（-0.2% vs -11.5%），OptimizeRx Corp自由现金流更多（$7.1M vs $-23.1M），过去两年OptimizeRx Corp的营收复合增速更高（28.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
OptimizeRx Corp是一家总部位于美国的数字健康科技企业，为生命科学公司、医疗机构及药房合作伙伴提供患者参与、药物可负担性和临床沟通相关解决方案，核心产品包括数字购药优惠工具、患者支持项目等，助力提升药物可及性与用药依从性。
LAB vs OPRX — 直观对比
营收规模更大
OPRX
是对方的1.6倍
$19.6M
营收增速更快
OPRX
高出11.2%
-11.5%
净利率更高
OPRX
高出193.0%
-177.4%
自由现金流更多
OPRX
多$30.2M
$-23.1M
两年增速更快
OPRX
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $32.2M |
| 净利润 | $-34.7M | $5.0M |
| 毛利率 | 48.5% | 74.8% |
| 营业利润率 | -168.5% | 26.6% |
| 净利率 | -177.4% | 15.6% |
| 营收同比 | -11.5% | -0.2% |
| 净利润同比 | -28.8% | 6535.9% |
| 每股收益（稀释后） | $-0.09 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABOPRX
| Q4 25 | — | $32.2M | ||
| Q3 25 | $19.6M | $26.1M | ||
| Q2 25 | $21.8M | $29.2M | ||
| Q1 25 | $40.8M | $21.9M | ||
| Q4 24 | — | $32.3M | ||
| Q3 24 | $22.1M | $21.3M | ||
| Q2 24 | $22.5M | $18.8M | ||
| Q1 24 | $45.5M | $19.7M |
净利润LABOPRX
| Q4 25 | — | $5.0M | ||
| Q3 25 | $-34.7M | $779.0K | ||
| Q2 25 | $-33.5M | $1.5M | ||
| Q1 25 | $-26.0M | $-2.2M | ||
| Q4 24 | — | $-78.0K | ||
| Q3 24 | $-26.9M | $-9.1M | ||
| Q2 24 | $-45.7M | $-4.0M | ||
| Q1 24 | $-32.2M | $-6.9M |
毛利率LABOPRX
| Q4 25 | — | 74.8% | ||
| Q3 25 | 48.5% | 67.2% | ||
| Q2 25 | 48.8% | 63.8% | ||
| Q1 25 | 48.4% | 60.9% | ||
| Q4 24 | — | 68.1% | ||
| Q3 24 | 54.9% | 63.1% | ||
| Q2 24 | 46.1% | 62.2% | ||
| Q1 24 | 53.1% | 62.0% |
营业利润率LABOPRX
| Q4 25 | — | 26.6% | ||
| Q3 25 | -168.5% | 7.9% | ||
| Q2 25 | -118.1% | 10.9% | ||
| Q1 25 | -80.8% | -9.6% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | -120.9% | -40.2% | ||
| Q2 24 | -134.5% | -19.9% | ||
| Q1 24 | -132.2% | -25.5% |
净利率LABOPRX
| Q4 25 | — | 15.6% | ||
| Q3 25 | -177.4% | 3.0% | ||
| Q2 25 | -153.7% | 5.2% | ||
| Q1 25 | -63.8% | -10.0% | ||
| Q4 24 | — | -0.2% | ||
| Q3 24 | -122.0% | -42.8% | ||
| Q2 24 | -203.3% | -21.3% | ||
| Q1 24 | -70.6% | -35.0% |
每股收益（稀释后）LABOPRX
| Q4 25 | — | $0.27 | ||
| Q3 25 | $-0.09 | $0.04 | ||
| Q2 25 | $-0.09 | $0.08 | ||
| Q1 25 | $-0.07 | $-0.12 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.07 | $-0.50 | ||
| Q2 24 | $-0.12 | $-0.22 | ||
| Q1 24 | $-0.27 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $23.4M |
| 总债务越低越好 | — | $26.3M |
| 股东权益账面价值 | $399.7M | $128.3M |
| 总资产 | $539.6M | $176.9M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资LABOPRX
| Q4 25 | — | $23.4M | ||
| Q3 25 | $129.4M | $19.5M | ||
| Q2 25 | $158.6M | $16.6M | ||
| Q1 25 | $150.9M | $16.6M | ||
| Q4 24 | — | $13.4M | ||
| Q3 24 | $210.6M | $16.1M | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABOPRX
| Q4 25 | — | $26.3M | ||
| Q3 25 | — | $28.8M | ||
| Q2 25 | — | $29.3M | ||
| Q1 25 | — | $33.8M | ||
| Q4 24 | — | $34.3M | ||
| Q3 24 | $55.2M | $36.8M | ||
| Q2 24 | $55.1M | $37.3M | ||
| Q1 24 | $55.0M | $37.8M |
股东权益LABOPRX
| Q4 25 | — | $128.3M | ||
| Q3 25 | $399.7M | $122.3M | ||
| Q2 25 | $424.5M | $119.3M | ||
| Q1 25 | $454.6M | $116.3M | ||
| Q4 24 | — | $117.0M | ||
| Q3 24 | $489.3M | $114.5M | ||
| Q2 24 | $510.3M | $121.0M | ||
| Q1 24 | $577.3M | $122.5M |
总资产LABOPRX
| Q4 25 | — | $176.9M | ||
| Q3 25 | $539.6M | $170.3M | ||
| Q2 25 | $557.0M | $169.3M | ||
| Q1 25 | $579.6M | $167.8M | ||
| Q4 24 | — | $171.2M | ||
| Q3 24 | $681.5M | $165.2M | ||
| Q2 24 | $708.7M | $172.9M | ||
| Q1 24 | $777.7M | $176.4M |
负债/权益比LABOPRX
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | 0.11× | 0.32× | ||
| Q2 24 | 0.11× | 0.31× | ||
| Q1 24 | 0.10× | 0.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $7.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $7.1M |
| 自由现金流率自由现金流/营收 | -118.1% | 22.0% |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $18.7M |
8季度趋势，按日历期对齐
经营现金流LABOPRX
| Q4 25 | — | $7.1M | ||
| Q3 25 | $-22.2M | $3.2M | ||
| Q2 25 | $-20.7M | $4.6M | ||
| Q1 25 | $-30.3M | $3.9M | ||
| Q4 24 | — | $198.0K | ||
| Q3 24 | $-27.9M | $1.8M | ||
| Q2 24 | $-39.0M | $782.0K | ||
| Q1 24 | $-62.5M | $2.1M |
自由现金流LABOPRX
| Q4 25 | — | $7.1M | ||
| Q3 25 | $-23.1M | $3.2M | ||
| Q2 25 | $-22.6M | $4.6M | ||
| Q1 25 | $-35.3M | $3.8M | ||
| Q4 24 | — | $181.0K | ||
| Q3 24 | $-30.1M | $1.8M | ||
| Q2 24 | $-41.0M | $737.0K | ||
| Q1 24 | $-63.3M | $2.1M |
自由现金流率LABOPRX
| Q4 25 | — | 22.0% | ||
| Q3 25 | -118.1% | 12.2% | ||
| Q2 25 | -103.6% | 15.6% | ||
| Q1 25 | -86.6% | 17.5% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | -136.4% | 8.3% | ||
| Q2 24 | -182.2% | 3.9% | ||
| Q1 24 | -138.9% | 10.6% |
资本支出强度LABOPRX
| Q4 25 | — | 0.0% | ||
| Q3 25 | 4.5% | 0.0% | ||
| Q2 25 | 8.7% | 0.0% | ||
| Q1 25 | 12.4% | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 10.2% | 0.1% | ||
| Q2 24 | 8.6% | 0.2% | ||
| Q1 24 | 1.7% | 0.2% |
现金转化率LABOPRX
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 4.11× | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
OPRX
暂无分部数据
